| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-48336SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1800SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-106SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-615SS | |||
| Azide and BSA Free | NBP2-80617 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-89062SS | |||
| Azide and BSA Free | NBP2-80895 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2527SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22119SS | |||
| Azide and BSA Free | NBP2-80814 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-202SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-500SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-428SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22115SS | |||
| Azide and BSA Free | NBP2-80618 | |||
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Increased lactate level detected in the hippocampus of streptozotocin-injected mice fed an HFD (HFD + STZ).b LDHA and LDHB protein levels were measured by western blot assay. c LDHA protein levels were quantified by the ratio to B-actin in the hippocampus. f Cropped images of LDHA and LDHB in the cortex. g Quantified LDHA in the cortex by the ratio to B-actin. Values are expressed as means +/- SEMs (n = 5 for both groups). * p < 0.05. Image collected and cropped by Citeab from the following publication (Hyperpolarized [1-13C]lactate flux increased in the hippocampal region in diabetic mice. Mol Brain (2019) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Western-Blot-NBP1-48336-img0020.jpg "Western Blot: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Increased lactate level detected in the hippocampus of streptozotocin-injected mice fed an HFD (HFD + STZ).b LDHA and LDHB protein levels were measured by western blot assay. c LDHA protein levels were quantified by the ratio to B-actin in the hippocampus. f Cropped images of LDHA and LDHB in the cortex. g Quantified LDHA in the cortex by the ratio to B-actin. Values are expressed as means +/- SEMs (n = 5 for both groups). * p < 0.05. Image collected and cropped by Citeab from the following publication (Hyperpolarized [1-13C]lactate flux increased in the hippocampal region in diabetic mice. Mol Brain (2019) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Immunocytochemical analysis of Lactate Dehydrogenase A in HeLa cells](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-48336-img0009.jpg)
![Immunohistochemistry: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Staining of postnatal day 8(P8) Plp-EGFP transgenic mice brain section. Image from verified customer review.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Immunohistochemistry-NBP1-48336-img0013.jpg)
![Flow Cytometry: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - An intracellular stain was performed on HeLa cells with Lactate Dehydrogenase A/LDHA Antibody NBP1-48336AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Flow-Cytometry-NBP1-48336-img0021.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Analysis of Lactate Dehydrogenase A in HeLa whole cell lysates.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Western-Blot-NBP1-48336-img0011.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Analysis of Lactate Dehydrogenase A in NIH/3T3 whole cell lysates.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Western-Blot-NBP1-48336-img0012.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Lactate Dehydrogenase A expression in bovine skeletal muscle lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Western-Blot-NBP1-48336-img0014.jpg)
![Western Blot: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Lactate Dehydrogenase A expression in porcine skeletal muscle lysate. Image from verified customer review.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Western-Blot-NBP1-48336-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - The effect of the co-culturing of cancer cells and fibroblasts on the expression of Hk2 and Ldha. In the co-cultures, the expression of Ldha was reduced in cancer cells, but was elevated in fibroblasts. Bar = 50 um. The ratio of the fluorescence of Hk2 and Ldha to beta-actin in the MLF monoculture was assumed to be 1. All the experiments were performed in triplicate and obtained similar results, and representative data from one experiment are shown in the figure. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31947613/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Lactate Dehydrogenase A-LDHA Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-48336-img0022.jpg)
![Immunohistochemistry: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Staining of Lactate Dehydrogenase A in lung tissue.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Immunohistochemistry-NBP1-48336-img0010.jpg)
![Flow Cytometry: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336]](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Flow-Cytometry-NBP1-48336-img0017.jpg)
![Simple Western: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Lane view shows a specific band for Lactate dehydrogenase A in 0.1 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system.](http://images.novusbio.com/fullsize/Lactate-Dehydrogenase-A-LDHA-Antibody---BSA-Free-Simple-Western-NBP1-48336-img0016.jpg)
![Simple Western: Lactate Dehydrogenase A/LDHA Antibody - BSA Free [NBP1-48336] - Protein changes in ONHAs corroborate bioenergetics data. (A) Glucose transporter-1 protein levels in Stretched ONH astrocytes are significantly higher than Control (*p = 0.0225, n = 7 Control, n = 8 Stretch). Retinal lysate from a 2 month-old mouse was used as a positive control for each protein analyzed, while negative control was the signal obtained when no primary antibody was included in the capillary. (B) Lactate dehydrogenase-A, the astrocyte-specific isoform of the enzyme that catalyzes the interconversion of pyruvate & lactate, has equivalent protein levels in Control & Stretch ONH astrocytes. (C) Glucose-6-phosphate dehydrogenase, the enzyme that shunts glucose into the pentose phosphate pathway, is no different in Control & Stretch ONH astrocytes. (D) Glutamine synthetase, the enzyme that synthesizes glutamine from glutamate, is no different in Control & Stretch ONH astrocytes. (E) The monomeric form of glutamate-aspartate transporter (GLAST) has significantly higher protein levels in the Stretch as compared to the Control ONH astrocytes (p = 0.020; n = 4 Control, n = 5 Stretch). (F) GLAST dimer protein levels are no different in Control & Stretch ONH astrocytes. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35992925), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-48336_rabbit-polyclonal-lactate-dehydrogenase-a-ldha-antibody-310202416171412.jpg)
![Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - Western Blot Image of anti-DEC1. Whole cell protein from A431 (lane 1) and PC3 (lane 2) was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2 ug/ml anti-DEC1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Western-Blot-NB100-1800-img0011.jpg "Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - Western Blot Image of anti-DEC1. Whole cell protein from A431 (lane 1) and PC3 (lane 2) was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2 ug/ml anti-DEC1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: DEC1 Antibody - BSA Free [NB100-1800] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-DEC1 (NB100-1800) at a 1:200 dilution overnight at 4C and detected with and anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with and anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NB100-1800-img0009.jpg)
![Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Immunohistochemical detection of DEC1 in myocardial and stromal cells. Representative images of one WT heart treated with TAC and sham at four weeks. The black square shows representative large images, magnification 400x. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/20/19/4967) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunohistochemistry-NB100-1800-img0017.jpg)
![Flow Cytometry: DEC1 Antibody - BSA Free [NB100-1800] - An intracellular stain was performed on A431 cells with DEC1 Antibody NB100-1800AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Flow-Cytometry-NB100-1800-img0016.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - DEC1 expression decreases in HeLa cells under apoptosis. Western blotting images of cleaved-poly (ADP-ribose) polymerase (PARP), cleaved-caspase 3, Bcl-2, DEC1, DEC2, SOX2, c-MYC and actin treated with 10, 20, and 50 uM cisplatin or mock in HeLa and SiHa cells. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33089188/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DEC1 Antibody - BSA Free-Western Blot-NB100-1800-img0018.jpg)
![Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - Western blot analysis of DEC1 in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Western-Blot-NB100-1800-img0001.jpg)
![Immunohistochemistry-Paraffin: DEC1 Antibody - BSA Free [NB100-1800] - P. gingivalis-challenged rat maxilla using DEC1 antibody at 1:100. Heat mediated antigen retrieval (sodium citrate buffer pH 6.0) was performed. Counter-stained with hematoxylin. Image from verified customer review.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB100-1800-img0012.jpg)
![Immunoprecipitation: DEC1 Antibody - BSA Free [NB100-1800] - Samples: Whole cell lysate from HeLa (50 ug for WB) and 293T (1 mg/IP, 20% of IP loaded) cells. Antibodies: Affinity purified rabbit anti-DEC1 antibody BL2928 used for WB at 0.1 ug/ml (A) and 1 ug/ml (B) and for IP at 3 ug/mg lysate. DEC1 was also immunoprecipitated using rabbit anti-DEC1 antibodies BL2926 and BL2927, which recognize upstream epitopes. Detection: Chemiluminescence with exposure times of 3 minutes (A) and 30 seconds (B).](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunoprecipitation-NB100-1800-img0007.jpg)
![Simple Western: DEC1 Antibody - BSA Free [NB100-1800] - Simple Western lane view shows a specific band for DEC1 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Simple-Western-NB100-1800-img0008.jpg)
![<b>Genetic Strategies Validation. </b>Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800] - (B) HSC-2 cells were used to perform knockdown assays for three primary antibodies: HIF1A, DEC1, and DEC2 9. Real-time RT-PCR evaluated expression levels of MSH2, MBD4, MRE11A, BRCA1, and RAD51. Value displayed above the bar represents the ratio of expression under hypoxic conditions compared with that under normoxia. Citation: Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, et al. (2018) Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE 13(2): e0192136. //doi.org/10.1371/journal.pone.0192136](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunoblotting-NB100-1800-img0013.jpg)
![Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800] - DNA-DRR genes promoter activities decreased with DEC. (B) The DEC1 or DEC2 expression plasmids (B), each reporter, and DEC1 or delta basic DEC1 expression plasmids (C) were co-transfected into HepG2. Under normoxic conditions they were then incubated for 36 hours. A dual-luciferase assay system determined luciferase activities. Citation: Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, et al. (2018) Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE 13(2): e0192136. //doi.org/10.1371/journal.pone.0192136](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunoblotting-NB100-1800-img0014.jpg)
![<b>Genetic Strategies Validation. </b>Immunoblotting: DEC1 Antibody - BSA Free [NB100-1800] - Knockdown assays in HSC-2 cells for HIF1A, DEC1, and DEC2. After transfecting and culturing non-specific siRNA or targeted siRNA into HSC-2, culturing them under normoxic and hypoxic conditions (24 hours), RT-PCR evaluated expression levels of the three primary antibodies. Citation: Nakamura H, Bono H, Hiyama K, Kawamoto T, Kato Y, Nakanishi T, et al. (2018) Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions. PLoS ONE 13(2): e0192136. //doi.org/10.1371/journal.pone.0192136](http://images.novusbio.com/fullsize/DEC1-Antibody---BSA-Free-Immunoblotting-NB100-1800-img0015.jpg)
![Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Dec1 expression is increased in the myocardial cells of cardiac hypertrophy & myocardial infarction. Immunohistochemical detection of Dec1 in human cardiac diseases. Representative image of Dec1 immunoreactivities from case 1 to case 8. Case 1 (control) had no significant findings (NS). Cases 2 to 6 are cardiac hypertrophy (CH). Case 7 is acute myocardial infarction (AMI), & case 8 is an old myocardial infarction (OMI). Magnification 400×. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31597354), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1800_rabbit-polyclonal-dec1-antibody-31020241539591.jpg)
![Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - DEC1 has anti-apoptotic effects in HeLa cells under apoptosis. (A) Cell viability of HeLa, SiHa & Caski cells with (+) or without (−) cisplatin & empty vector, DEC1 or DEC2 plasmid treatment was determined. The absorbance (OD480/OD650) at 0 & 24 h is shown. The value of cell viability of control 0 h regarded as 10. Data are expressed as mean values ± SE (bars) of three independent samples. * p < 0.05, as determined using t-test. (B) Western blotting images of DEC1, DEC2, cleaved-PARP, cleaved-caspase 3, Bcl-2, beta -catenin, SOX2, c-MYC & actin treated with 50 μM cisplatin & empty vector, DEC1 or DEC2 plasmid in HeLa cells. Western blot analysis was repeated three times & similar results were obtained. (C) SOX2 & c-MYC mRNA expressions in HeLa & SiHa cells with cisplatin & empty vector, DEC1 or DEC2 plasmid treatment. Data are expressed as mean values ± SE (bars) of three independent samples. * p < 0.01, as determined using t-test. qPCR was repeated three times & similar results were obtained. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1800_rabbit-polyclonal-dec1-antibody-310202415535182.jpg)
![Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Representative images for the immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Each panel shows ×200 magnification. DEC1 immunoreactivities in (A) non-cancerous cells, (B) shallow cancer cells, & (C) deep cancer cells of case 14. DEC1 immunoreactivity in (D) SCC of case 1, & in (E) AC of case 5, respectively. DEC2 immunoreactivities in (F) non-cancerous cells, (G) & cancer cells of case 15. SOX2 immunoreactivities in (H) non-cancerous cells, (I) shallow cancer cells, & (J) deep cancer cells of case 14. c-MYC immunoreactivities in (K) non-cancerous cells, (L) & cancer cells of case 15. Vimentin immunoreactivities in (M) non-cancerous vascular cells, (N) & cancerous vascular cells of case 14. Black arrows in E-G show nuclear staining. The white arrow in E indicates non-cancerous cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1800_rabbit-polyclonal-dec1-antibody-31020241555240.jpg)
![Western Blot: DEC1 Antibody - BSA Free [NB100-1800] - DEC1 expression decreases in HeLa cells under apoptosis. (A) Endogenous DEC1 protein expressions in HeLa & SiHa cells. Western blotting images of beta -catenin, DEC1, DEC2, SOX2, c-MYC & actin in HeLa & SiHa cells. The western blot analysis was repeated three times & similar results were obtained. (B) Cell viability of HeLa & SiHa cells with (+) or without (−) cisplatin treatment was determined. The absorbance (OD480/OD650) at 0 & 24 h is shown. The value of cell viability of control 0 h regarded as 10, which means each basal value without treatment. Data are expressed as mean values ± SE (bars) of three independent samples. * p <0.01, as determined using Dunnett’s test. Cis: Cisplatin treatment. (C) Western blotting images of cleaved-poly (ADP-ribose) polymerase (PARP), cleaved-caspase 3, Bcl-2, DEC1, DEC2, SOX2, c-MYC & actin treated with 10, 20, & 50 μM cisplatin or mock in HeLa & SiHa cells. The western blot analysis was repeated three times & similar results were obtained (D) DEC1, DEC2 & SOX2 mRNA expressions in HeLa & SiHa cells with (+) or without (−) cisplatin treatment. Data are expressed as mean values ± SE (bars) of three independent samples. * p < 0.01, as determined using t-test. qPCR was repeated three times & similar results were obtained. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1800_rabbit-polyclonal-dec1-antibody-310202415541956.jpg)
![Immunohistochemistry: DEC1 Antibody - BSA Free [NB100-1800] - Immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Representative images for the immunoreactivities of DEC1, DEC2, SOX2, c-MYC & vimentin in cervical cancer tissues. Each panel shows ×200 magnification. DEC1 immunoreactivities in (A) non-cancerous cells, (B) shallow cancer cells, & (C) deep cancer cells of case 14. DEC1 immunoreactivity in (D) SCC of case 1, & in (E) AC of case 5, respectively. DEC2 immunoreactivities in (F) non-cancerous cells, (G) & cancer cells of case 15. SOX2 immunoreactivities in (H) non-cancerous cells, (I) shallow cancer cells, & (J) deep cancer cells of case 14. c-MYC immunoreactivities in (K) non-cancerous cells, (L) & cancer cells of case 15. Vimentin immunoreactivities in (M) non-cancerous vascular cells, (N) & cancerous vascular cells of case 14. Black arrows in E-G show nuclear staining. The white arrow in E indicates non-cancerous cells. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33089188), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1800_rabbit-polyclonal-dec1-antibody-31020241612633.jpg)
![Western Blot: p19ARF/CDKN2A Antibody [NB200-106] - Analysis of p19ARF/CDKN2A in (A) NIH/3T3 and (B) MEF cells.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-Western-Blot-NB200-106-img0010.jpg "Western Blot: p19ARF/CDKN2A Antibody [NB200-106] - Analysis of p19ARF/CDKN2A in (A) NIH/3T3 and (B) MEF cells.")
![Immunocytochemistry/Immunofluorescence: p19ARF/CDKN2A Antibody [NB200-106] - Antibody was tested in MEF cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/p19ARF-Antibody-Immunocytochemistry-Immunofluorescence-NB200-106-img0004.jpg)
![Immunohistochemistry: p19ARF/CDKN2A Antibody [NB200-106] - Adult mouse kidney (glomerulus). Image from verified customer review.](http://images.novusbio.com/fullsize/p19ARF-Antibody-Immunocytochemistry-Immunofluorescence-NB200-106-img0006.jpg)
![Immunohistochemistry-Paraffin: p19ARF/CDKN2A Antibody [NB200-106] - Analysis of FFPE mouse spleen using p19ARF/CDKN2A antibody at 10 ug/mL on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining in the germinal centers of spleen was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/p19ARF-Antibody-Immunohistochemistry-Paraffin-NB200-106-img0005.jpg)
![Western Blot: Caveolin-1 Antibody (7C8) [NB100-615] - Detection of caveolin in 3T3 cell lysates (50 ug). Lanes 1 and 2: 1:4000. Lanes 3 and 4: 1:1000. Detection by ECL: 5 minute exposure.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Western-Blot-NB100-615-img0010.jpg "Western Blot: Caveolin-1 Antibody (7C8) [NB100-615] - Detection of caveolin in 3T3 cell lysates (50 ug). Lanes 1 and 2: 1:4000. Lanes 3 and 4: 1:1000. Detection by ECL: 5 minute exposure.")
![Immunocytochemistry/Immunofluorescence: Caveolin-1 Antibody (7C8) [NB100-615] - Subcellular localization of mPARM-1 and hPARM-1 (full-length and mutant proteins). NIH/3T3 cells transiently expressing hPARM-1-GFP or deltaCT-GFP were fixed, immunostained for caveolin-1 (1:100, Novus Biologicals), and examined by confocal fluorescence microscopy. For hPARM-1-GFP-caveolin-1 co-localization, cells that demonstrated cell membrane PARM-1 localization were chosen. All co-localizations were observed following merging images of GFP-tagged proteins with those of Golgi, endosomes, plasma membrane, alpha-tubulin or caveolin-1 labeling. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-12-84), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunocytochemistry-Immunofluorescence-NB100-615-img0014.jpg)
![Immunohistochemistry-Frozen: Caveolin-1 Antibody (7C8) [NB100-615] - Immunofluorescence of human adipose tissue. Primary antibody at 1:250. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunohistochemistry-Frozen-NB100-615-img0015.jpg)
![Flow Cytometry: Caveolin-1 Antibody (7C8) [NB100-615] - An intracellular stain was performed on HeLa cells with Caveolin-1 Antibody (7C8) NB100-615APC (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to allophycocyanin.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Flow-Cytometry-NB100-615-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Caveolin-1 Antibody (7C8) [NB100-615] - Antibody at 1:200 dilution (ON incubation) on EaHy926 endothelial cell line showing a clear localization in lipid raft/membrane. Photo courtesy of Alberto Davalos, Yale School of Medicine.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunocytochemistry-Immunofluorescence-NB100-615-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: Caveolin-1 Antibody (7C8) [NB100-615] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-Caveolin-1 [7C8] conjugated to Alexa Fluor 488 (NB100-615AF488) at 20 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Immunocytochemistry-Immunofluorescence-NB100-615-img0013.jpg)
![Flow Cytometry: Caveolin-1 Antibody (7C8) [NB100-615] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using Caveolin 1 antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Flow-Cytometry-NB100-615-img0008.jpg)
![Flow Cytometry: Caveolin-1 Antibody (7C8) [NB100-615] - An intracellular stain was performed on HeLa cells with Caveolin-1 Antibody (7C8) NB100-615 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/Caveolin-1-Antibody-7C8-Flow-Cytometry-NB100-615-img0011.jpg)
![Western Blot: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Analysis of Osteopontin expression in U2OS whole cell lysate.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Western-Blot-NB110-89062-img0007.jpg "Western Blot: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Analysis of Osteopontin expression in U2OS whole cell lysate.")
![Immunocytochemistry/Immunofluorescence: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Osteopontin antibody was tested at 1:50 in U2OS cells with FITC (green). Nuclei and actin were counterstained with Dapi (blue) and Phalloidin (red).](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunocytochemistry-Immunofluorescence-NB110-89062-img0008.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Immunohistological results at 12 weeks for (A) Group I, (B) Group II (C) Group III.The pictures are arranged by staining technique (columns) and by the investigated treatment (rows). Areas that stained positive for osteopontin are indicated by red arrowheads. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/3513) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0012.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Osteogenic differentiation in 3D. Immunostaining for osteopontin (OPN) and nuclear DAPI in 3D cultures after 5 weeks. Scale bar = 50 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34948393/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0013.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Analysis of Osteopontin on human lung adenocarcinoma.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0009.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks. The pictures are arranged by staining technique (columns) and the investigated treatment (rows). Areas that stained positive for osteocalcin and osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/3513) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Immunohistochemistry-NB110-89062-img0011.jpg)
![Simple Western: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Simple Western lane view shows a specific band for Osteopontin in 0.5 mg/ml of Human Breast Cancer lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody](http://images.novusbio.com/fullsize/Osteopontin-OPN-Antibody-1B20-BSA-Free-Simple-Western-NB110-89062-img0010.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Photomicrographs of immunostaining for osteocalcin & osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) & the investigated treatment (rows). Areas that stained positive for osteocalcin & osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected & cropped by CiteAb from the following publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89062_mouse-monoclonal-osteopontin-opn-antibody-1b20-3102024153560.jpg)
![Immunohistochemistry: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Photomicrographs of immunostaining for osteocalcin & osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) & the investigated treatment (rows). Areas that stained positive for osteocalcin & osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected & cropped by CiteAb from the following publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89062_mouse-monoclonal-osteopontin-opn-antibody-1b20-31020241534321.jpg)
![Western Blot: Osteopontin/OPN Antibody (1B20) - BSA Free [NB110-89062] - Photomicrographs of immunostaining for osteocalcin & osteopontin in (A) Group I, (B) Group II (C) Group III at 6 weeks.The pictures are arranged by staining technique (columns) & the investigated treatment (rows). Areas that stained positive for osteocalcin & osteopontin are indicated by red arrowheads. NB, new bone; OS, osteoid; FM, fatty marrow. Image collected & cropped by CiteAb from the following publication (//peerj.com/articles/3513), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-89062_mouse-monoclonal-osteopontin-opn-antibody-1b20-310202415394515.jpg)
![Western Blot: LOX Antibody [NB100-2527] - LOX secretion and activity in response to tumor cell irradiation. Western blot of LOX zymogen (50 kDa) and active form (32 kDa) in conditioned media derived from irradiated A549 lung carcinoma cells 16-20 h after irradiation and quantification of band intensities from 3 independent experiments. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-532) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NB100-2527-img0015.jpg "<b>Biological Strategies Validation. </b>Western Blot: LOX Antibody [NB100-2527] - LOX secretion and activity in response to tumor cell irradiation. Western blot of LOX zymogen (50 kDa) and active form (32 kDa) in conditioned media derived from irradiated A549 lung carcinoma cells 16-20 h after irradiation and quantification of band intensities from 3 independent experiments. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-532) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: LOX Antibody [NB100-2527] - Expression of Lox and Loxl1-Loxl4 mRNAs in orthotopic rat prostate tumours and in the surrounding normal rat prostate tissue. Representative sections from a 10-day orthotopic AT-1 rat prostate tumour (T), tumour-adjacent normal rat prostate tissue (N), and tumour-free control rat prostate tissue stained for LOX (inserts show LOX staining in higher magnifications). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep19608), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-Paraffin-NB100-2527-img0017.jpg)
![Simple Western: LOX Antibody [NB100-2527] - Simple Western shows a specific band for LOX in 1.0 mg/ml of HeLa cell lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LOX-Antibody-Simple-Western-NB100-2527-img0009.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody [NB100-2527] - LOX in fibrotic mice lung tissue. Primary antibody at 1:100, incubated overnight at 4C. Image from verified customer review.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-Paraffin-NB100-2527-img0011.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: LOX Antibody [NB100-2527] - IR-induced LOX promotes the invasive capacity of naive tumor cells. Western blot of LOX in conditioned media derived from untreated and irradiated A549 cells, transfected with siLuc-control or siLOX-RNA. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-532) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-Antibody-Knockdown-Validated-NB100-2527-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: LOX Antibody [NB100-2527] - LOX antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/LOX-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2527-img0007.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: LOX Antibody [NB100-2527] - IR-enhanced LOX in tumor xenografts. Tumor tissue from A549-derived tumor xenografts treated with 1 x 10 Gy and 2 x 10 Gy (with 12 h between fractions) and evaluated by immunohistochemistry for LOX at different time points after irradiation. Whole tumor sections were quantified for specific LOX-staining intensity. Each treatment group consists of 3 animals. At least 3 sections per tumor/animal were analyzed. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-532) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-NB100-2527-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: LOX Antibody [NB100-2527] - Staining in human fibroblasts. Image from verified customer review.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2527-img0013.jpg)
![Western Blot: LOX Antibody [NB100-2527] - Analysis of LOX in human kidney using NB100-2527.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NB100-2527-img0005.jpg)
![Immunohistochemistry: LOX Antibody [NB100-2527] - Staining of LOX in mouse stomach.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-NB100-2527-img0006.jpg)
![Western Blot: LOX Antibody [NB100-2527] - Patupilone counteracts hypoxia- but not IR-induced LOX-secretion. (A) Western blot of basal & IR-induced LOX in conditioned media derived from patupilone-untreated or patupilone-pretreated (0.5 nM) cells & quantification of band intensities from 3 independent experiments. (B) Western blot of basal & hypoxia-induced LOX in conditioned media derived from patupilone-untreated or patupilone-pretreated (0.5 nM) cells & quantification of band intensities from 3 independent experiments. (C) LOX gene transcription 16 h after irradiation & hypoxia, determined by RT-PCR, averaged over 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-532), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2527_rabbit-polyclonal-lox-antibody-310202415363721.jpg)
![Western Blot: iNOS Antibody (4E5) [NBP2-22119] - Analysis using iNOS mouse mAb against Jurkat (1), Jurkat (2), A549 (3), HeLa (4), NIH3T3 (5) and MCF-7 (6) cell lysate.](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-Western-Blot-NBP2-22119-img0007.jpg "Western Blot: iNOS Antibody (4E5) [NBP2-22119] - Analysis using iNOS mouse mAb against Jurkat (1), Jurkat (2), A549 (3), HeLa (4), NIH3T3 (5) and MCF-7 (6) cell lysate.")
![Immunohistochemistry-Paraffin: iNOS Antibody (4E5) [NBP2-22119] - Analysis of paraffin-embedded breast cancer tissues using iNOS mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-Immunohistochemistry-Paraffin-NBP2-22119-img0006.jpg)
![Flow Cytometry: iNOS Antibody (4E5) [NBP2-22119] - An intracellular stain was performed on A549 cells with NBP2-22119APC (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated with antibody at 1 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to allophycocyanin (APC).](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-Flow-Cytometry-NBP2-22119-img0011.jpg)
![Flow Cytometry: iNOS Antibody (4E5) [NBP2-22119] - An intracellular stain was performed on A549 cells with NBP2-22119PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated with antibody at 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin (PE).](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-Flow-Cytometry-NBP2-22119-img0010.jpg)
![Western Blot: iNOS Antibody (4E5) [NBP2-22119] - Analysis using iNOS mAb against human iNOS (AA: 997-1058) recombinant protein. (Expected MW is 32.6 kDa)](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-Western-Blot-NBP2-22119-img0002.jpg)
![Flow Cytometry: iNOS Antibody (4E5) - BSA Free [NBP2-22119] - An intracellular stain was performed on NIH3T3 cells with iNOS Antibody (4E5) NBP2-22119 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-BSA-Free-Flow-Cytometry-NBP2-22119-img0013.jpg)
![Immunohistochemistry-Paraffin: iNOS Antibody (4E5) [NBP2-22119] - Analysis of paraffin-embedded liver cancer tissues using iNOS mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-Immunohistochemistry-Paraffin-NBP2-22119-img0009.jpg)
![Flow Cytometry: iNOS Antibody (4E5) - BSA Free [NBP2-22119] - An intracellular stain was performed on Caco-2 cells with iNOS Antibody (4E5) NBP2-22119 (blue) and a matched isotype control MAB002 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-BSA-Free-Flow-Cytometry-NBP2-22119-img0012.jpg)
![ELISA: iNOS Antibody (4E5) [NBP2-22119] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/iNOS-Antibody-4E5-ELISA-NBP2-22119-img0001.jpg)
![Western Blot: STEP Antibody (23E5) [NB300-202] - Analysis of STEP protein in striatal rat protein homogenates](http://images.novusbio.com/fullsize/STEP-Antibody-23E5-Western-Blot-NB300-202-img0002.jpg "Western Blot: STEP Antibody (23E5) [NB300-202] - Analysis of STEP protein in striatal rat protein homogenates")
![Immunohistochemistry-Paraffin: STEP Antibody (23E5) [NB300-202] - STEP was detected in immersion fixed paraffin-embedded sections of human brain basal ganglia using Mouse Anti-Human STEP (23E5) Monoclonal Antibody (Catalog # NB300-202) at 1:100 for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm in neurons.](http://images.novusbio.com/fullsize/STEP-Antibody-23E5-Immunohistochemistry-Paraffin-NB300-202-img0003.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction by CoCl2 on Caki-1 cell lysate. HIF-1 alpha antibody (H1alpha67) [NB100-105]. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0019.jpg "<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction by CoCl2 on Caki-1 cell lysate. HIF-1 alpha antibody (H1alpha67) [NB100-105]. Western blot image submitted by a verified customer review.")
![<b>Biological Strategies Validation. </b>Simple Western: HIF-1 alpha Antibody Pack [NB100-900WB] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/mL of hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. HIF-1 alpha Antibody [NB100-449].](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Simple-Western-NB100-900WB-img0018.jpg)
![Simple Western: HIF-1 alpha Antibody Pack [NB100-900WB] - Image shows a specific band for HIF-1 alpha in 0.2 mg/mL of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Simple-Western-NB100-900WB-img0022.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Naive CD4 T cells from WT, VHL-deficient (Vhl KO), or HIF-1 alpha-deficient (HIF-1 alpha KO) mice were differentiated under IL-22-skewing conditions for a total of 60 h. Some cells remained at normoxia for the duration of the culture (N); others were at normoxia for 35 h and then hypoxia (1% O2) for 24 h (H). At 60 h, nuclear extracts were harvested, and HIF-1 alpha and Lamin B1 levels were analyzed by Western blot. Image from verified customer review. HIF-1 alpha Antibody (H1alpha67) [NB100-105]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Knockout-Validated-NB100-900WB-img0020.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Normoxic pre-treatment sensitizes glioma cells to radiation after graded chronic hypoxic (GCH) exposure. The results of anchorage-independent colony forming assays are shown for U87, U87-luc, GL261 glioma cells and 0308 GSCs after 5 Gy radiation exposure under varying O2 conditions. For easier comparisons among cell types, raw values are expressed as a % of the cell type's negative (non-irradiated) control and the means & SEMs are plotted. Also shown are Western blots of nuclear HIF-1alpha at the time of irradiation. Corresponding Western blots of lamin A/C are shown as a loading control. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0111199) licensed under a CC-BY license. HIF-1 alpha Antibody [NB100-479]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0015.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Morphological alterations induced by DMOG are HIF-1alpha dependent. glEND.2 cells were stably transfected with shGFP, shHIF-1alpha or shHIF-2alpha. The clones were cultured under normoxic (N) or hypoxic (H, 1% O2) conditions, or treated with DMOG for 6 h. 30 ug protein of cellular protein were loaded for the detection of HIF-1alpha, and nuclear extracts (20 ug protein) were used for the detection of HIF-2alpha. Image collected and cropped by CiteAb from the following publication (//biosignaling.biomedcentral.com/articles/10.1186/1478-811X-11-80) licensed under a CC-BY license. HIF-1 alpha Antibody [NB100-449]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Knockdown-Validated-NB100-900WB-img0017.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Analysis of HIF-1 alpha in overexpression and endogenous HIF-1 alpha & HIF-2 alpha using anti-HIF-1 alpha antibody NB100-134. The data showed that HIF-1 alpha antibody did not react to HIF-2 alpha overexpression. Wester blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0021.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - HIF-1 alpha induction on Caki-1 cell lysate using CoCl2. Western blot image submitted by a verified customer review. HIF-1 alpha Antibody [NB100-449]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0016.jpg)
![Western Blot: HIF-1 alpha Antibody Pack [NB100-900WB] - Detection of HIF-1 alpha (125-130 kDa) from human placental villous explant total protein. HIF-1 alpha Antibody (HA111) [NB100-296]](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Pack-Western-Blot-NB100-900WB-img0023.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - Fractionated, compared to single exposure, radiation more profoundly suppressed TM and eNOS. Representative Western blot analysis and quantification of KLF2 (n = 5) and KLF4 (n = 3) levels in whole-cell lysates from nonirradiated (sham) and irradiated HUVECs 4 h and 24 h after exposure to either five fractions of 2 Gy (5 x 2 Gy) or single exposure to 10 Gy. Fractions delivered at 24-h intervals. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/eNOS Antibody - BSA Free-Western Blot-NB300-500-img0007.jpg "<b>Biological Strategies Validation. </b>Western Blot: eNOS Antibody - BSA Free [NB300-500] - Fractionated, compared to single exposure, radiation more profoundly suppressed TM and eNOS. Representative Western blot analysis and quantification of KLF2 (n = 5) and KLF4 (n = 3) levels in whole-cell lysates from nonirradiated (sham) and irradiated HUVECs 4 h and 24 h after exposure to either five fractions of 2 Gy (5 x 2 Gy) or single exposure to 10 Gy. Fractions delivered at 24-h intervals. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091/) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Expression of endothelial markers indicate functional endothelium in TEVG. Whole mount staining of native aorta and TEVG. VE-cadherin is a marker of cellular borders of endothelial cells (green). Endothelial nitric oxide synthase (eNOS) is a marker of a functional endothelium (red). DAPI is a nuclear stain (blue). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0120328), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB300-500-img0006.jpg)
![Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Staining of eNOS in human lung tissue.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB300-500-img0003.jpg)
![Immunohistochemistry-Paraffin: eNOS Antibody - BSA Free [NB300-500] - Mouse Carotid Artery stained with eNOS antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NB300-500-img0004.jpg)
![Immunohistochemistry: eNOS Antibody - BSA Free [NB300-500] - Staining of representative pulmonary artery endothelial cells from rats subjected to CON=Control Group, ALI=Acute lung injury Group, LV=Low tidal volume Group, VLV=Very low tidal volume Group, MV=Large tidal volume Group. Dark brown staining of indicates eNOS-positive cells. Magnification x400.](http://images.novusbio.com/fullsize/eNOS-Antibody---BSA-Free-Immunohistochemistry-NB300-500-img0005.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - Mevalonate pathway inhibitors reversed fractionated-radiation–induced suppression of KLF2 & its downstream target molecules. Representative Western blot analysis & quantification of KLF2, TM, & eNOS 4 h after exposure to five fractions of 2 Gy (a) in presence or absence of atorvastatin (1 μM) or GT3 (5 μM) & (b) in presence or absence of GGTi (10 μM) (n = 3). beta -actin served as a loading control. (n, number of independent experiments performed; a, significant statistical difference between nonirradiated & irradiated groups; b, significant statistical difference between fractionated irradiation & single exposure; *, p < 0.05; **, p < 0.01; ***, p < 0.001). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32382091), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-500_rabbit-polyclonal-enos-antibody-31020241534534.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - Upregulation of HMG-CoA reductase in shPLD2 cells decreases eNOS expression. (A) Representative western blot of HMG-CoA reductase in Scramble & shPLD2 cells. The regions of the Western blots containing the HMG-CoA reductase & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system (B) Quantification of western blots with HMG-CoA reductase normalized to actin (n = 4 experiments). (C) N-SIM microscopy of HMG-CoA reductase; Bar, 7.5 μM. (D) RT-PCR of HMG-CoA reductase in Scramble & shPLD2 cells (n = 3). (E) Western blot of eNOS after treatment with NFOT & Simvastatin. Representative image of 3 experiments. The regions of the Western blots (Suppl. Figure 2) containing the eNOS & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system. (F) Quantification of western blots with eNOS levels normalized to actin (n = 3). Comparisons without bars made to untreated Scramble values. (G) eNOS activity after treatment with Simvastatin (n = 7). Mean ± SEM; *p < 0.05; **p < 0.01; ***p ≤ 0.001; One-way ANOVA with Bonferroni’s Multiple Comparison Test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28831159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-500_rabbit-polyclonal-enos-antibody-310202416212339.jpg)
![Western Blot: eNOS Antibody - BSA Free [NB300-500] - The human PLD2 polymorphism R172C does not alter eNOS signaling but does decrease caveolin-1 protein levels. Overexpression of HA-tagged hPLD2 (A) & HA-R172C-PLD2 (B) in HeLa cells, visualized using anti-HA immunofluorescent staining (green). Arrowhead, PLD2 localization in filopodia; chevron, in peripheral actin ruffles; *, in dorsal actin ruffles; arrow, in subcortical actin network. Bar, 7.5 μM. Representative image of multiple experiments. (C) Representative western blot of eNOS after transfection of HA-hPLD2 or HA-R172C-PLD2 into shPLD2 cells. The regions of the Western blots containing the eNOS & actin immunoreactive bands were scanned & the relative abundance of the individual samples quantified using an Odyssey CLx imaging system. (D) Quantification of western blotting with eNOS levels normalized to actin (n = 3). (E) eNOS activity as measured by nitrate formation (n = 7). Lane 1 vs 2, P = 0.0021; lane 2 vs 3, P = 0.00035; lane 2 vs 4, P = 0.00012. (F–I) N-SIM microscopy of plasma membrane eNOS & caveolin-1. Bar, 7.5 μM. Representative image of multiple Scramble or shPLD2 cells imaged. Cells in H & I were selected for imaging based on expression of HA-hPLD2 or HA-R172C-PLD2 as visualized by anti-HA immunofluorescence in a separate channel (not shown). Mean ± SEM; *p < 0.05; **p < 0.01; ***p ≤ 0.001; One-way ANOVA with Bonferroni’s Multiple Comparison Test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28831159), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-500_rabbit-polyclonal-enos-antibody-310202416212351.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0007.jpg "Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.")
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Representative picture of western blot in histopathologically unchanged tissue (N) and primary cancerous tissue (C) from patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1 (Catalog # NB100-310), - PHD2 (Catalog # NB100-137), - PHD3 (Catalog # NB100-139) and -FIH-1/HIF-1AN Ab (Catalog # NB100-139), followed by incubation with goat anti-rabbit HRP-conjugated Ab. The membrane was stripped and incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-526), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0010.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - Detection of FIH-1 in rat brain tissue.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Immunohistochemistry-NB100-428-img0008.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Rat VSMC (vascular smoot muscle) cells treated (siFIH) or not (CTL) with a specific siRNA against FIH-1. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - (C) Cytoplasmic FIH-1 (lower band) and MMP14 expression levels in both aerobic and hypoxic conditions in the 3 cell lines. (E) siRNA targeting FIH-1 was used to assess whether FIH-1 had any effect on CAIX expression in MCF-7 cells cultured in 0.5% O2 conditions. cont, control. m, transfection reagent alone. scr, scrambled siRNA. pool, mixture of 4 siRNAs targeting FIH-1. 21, single siRNA targeting FIH-1. (F) FIH-1 and CAIX expression levels in aerobic MCF-7 cells treated with either siRNA against FIH-1 alone, or both 400 uM CoCl2 and siRNA together for 24, 48 and 72h. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28476026/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN Antibody-Knockdown Validated-NB100-428-img0011.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - 3D target protein expression in multicellular tumor spheroids3D expression analysis was carried out in the MCF-7, MDA-MB-231 & HBL-100 cell lines using multicellular tumor spheroids. The spheroids were cultured in spinner flasks for 1 week before fixation. Hypoxyprobe was used to examine the formation of hypoxic areas within the spheroids. NHE1, CAIX, MMP14 & FIH-1 expression was also analyzed. Incubation for an hour with PBS instead of primary antibody acted as a control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17143), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-428_rabbit-polyclonal-fih-1-hif-1an-antibody-310202415384122.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0003.jpg "Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.")
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of HepG2 cells using A) MCP1 mAb (green), DRAQ5 fluorescent DNA dye (blue), and Actin filaments have been labeled with Alexa Fluor-555 phalloidin (red). B) Staining without MCP1 mAb](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0011.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - HER2 activates NF-kB and upregulates CCL2. MGs from FVB wild-type and 22-week-old MMTV-HER2 mice stained against CCL2, HER2, and CCR2. Bars: 25 um. Inset, CCR2 signal, zoom factor 1x; full image in Supplementary Fig. 5i. CCL2 intensity was quantified using ROI tool in Metamorph (Supplementary Fig. 5h). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0009.jpg)
![Flow Cytometry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of A549 cells using MCP1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Flow-Cytometry-NBP2-22115-img0004.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mAb against human MCP1 (AA: 1-99) recombinant protein. (Expected MW is 36.5 kDa)](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - CCL2 staining in acini cultures from MMTV-HER2 MGs (20-24 weeks) grown for 5 days and then DMSO-treated (vehicle control, e), 1uM lapatinib (f) or 1 uM IKKi compound A (g) for 24 hrs. Bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Organotypic specimens were treated with anti-LIF for 72 h and then cultured with PBMCs for 24 h. CXCL9 and CCL2 mRNA expression levels are shown. Representative images (patient 4, 5, 6) of CFSE-stained PBMCs into Matrigel containing GBM specimens and IF of the indicated factors in organotypic tissues are displayed. Bars represent quantification of five different fields of each condition. Data are presented as mean +/- SD. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0012.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of paraffin-embedded liver cancer tissues using MCP1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-Paraffin-NBP2-22115-img0007.jpg)
![ELISA: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Red: Control Antigen (100ng), Purple: Antigen (10ng), Green: Antigen (50ng), Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-ELISA-NBP2-22115-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202415384136.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF represses CXCL9 through epigenetic silencing. a, b qRT-PCR analysis of the indicated genes in BMDMs. BMDMs were pre-incubated with 20 ng/ml LIF for 72 h & then stimulated with 5 ng/ml IFN gamma or 10 μg/ml IL4 during 6 h (a) or with 0.1, 0.5, 1 & 5 ng/ml IFN gamma for 24 h (b). c CXCL9 ELISA from BMDMs pre-incubated with 20 ng/ml LIF & then stimulated with 0.1 ng/ml IFN gamma for 24 h. d CXCL9 ELISA from human CD11b+sorted cells (77% CD11b+ CD14+, see Supplementary Fig. 7b, c) from human GBM cultured with 20 ng/ml LIF for 72 h & then with 0.1 ng/ml IFN gamma for 24 h. e ChIP of Tri-methyl-histone H3 (H3K27me3), EZH2 & acetyl-histone4 (H4ac) was performed in BMDMs treated with 20 ng/ml LIF for 72 h. Scheme shows the analysed CXCL9 promoter region. Representative data are presented as mean ± SD. f Representative images of IF of the indicated markers in human GBM organotypic slices (patients 1, 2, 3) incubated with 10 μg/ml anti-LIF for 3 days. Scale bar, 20 μm. (see Supplementary Fig. 8). Bottom, percentage of double positive cells relative to Iba1+ cells & percentage of CXCL9+ cells relative to the total number of cells. Data are mean of all patients ± SEM. Statistical analyses by Student’s t-test or Mann–Whitney T-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-3102024161360.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202416114760.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-31020241613617.jpg)